Breakthrough Therapies

Reach the Market Smarter and Faster: Breakthrough Therapies, Orphan Drug Designation, Fast Track ... and the Right Strategy

“Breakthrough” and “Fast Track” are frequently heard buzzwords in the pharmaceutical arena. Looking at development times of up to 17 years from early R&D to product approval with further two years for pricing and reimbursement, it appears that the biopharmaceutical industry is rather on a “Slow Track”. Despite significant advances in medical science, there are still numerous patients without appropriate treatment options.